The global novel drug delivery system market size was valued at USD 225.2 billion in 2021. It is projected to reach USD 379.5 billion by 2030, growing at a CAGR of 5.97% during the forecast period (2022–2030).
A novel drug delivery system is a novel approach to drug delivery that addresses the limitations of traditional drug delivery systems. Modern medicine cures a particular disease by targeting the affected zone inside a patient's body and transporting the drug to that area. The innovative drug delivery system (NDDS), according to the purview of this paper, aims to improve the efficacy of medications. NDDSs are used to improve drug stability, lessen adverse side effects, and boost the bioavailability of the medicine. The report keeps track of the money made from the sales of treatments based on NNDS to end users, i.e., finished novel drug delivery system formulations with API and other parts.
|Market Size||USD 379.5 billion by 2030|
|Fastest Growing Market||Europe|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
Due to their improved efficacy and fewer adverse effects, novel drug delivery systems (NDDS), including controlled drug delivery systems, are used for various medicinal treatments. Therapeutic agents that are safer and more effective while using an enhanced drug delivery mechanism represent advancements in the treatment of disease as well as attractive marketing prospects for pharmaceutical companies. These NDDS are regarded as the best drug delivery systems because they provide a precise dose of medication to the target place at the right time and pace, depending on the etiological and physiological requirements of the body. As a result, these drug delivery systems are frequently utilized to manage numerous chronic diseases, including neurological disorders, diabetes, kidney problems, and cardiovascular disease. The rise in the prevalence of various chronic diseases is likely to fuel the demand for drugs with controlled release mechanisms.
The development of new medications and biologics based on the molecular causes of human diseases is now possible due to several biology-related efforts. Lipid, protein, and polymer technologies with improved lipid distribution in the body are among the recently found drug delivery systems. This prevents drug degradation owing to the external environment and lowers the rate of drug clearance. Numerous innovative drug delivery systems, including nano beacon and mini beacons, Trojan horse nanoparticles, MEMS, and NEMS, have been created due to the application of nanotechnology in the pharmaceutical industry (micro and nanoelectromechanical systems). A revolutionary lipid-based system called "Cochleate delivery vehicles" offers a cutting-edge technology platform for medications' systemic and oral delivery.
Governments worldwide have created regulatory authorities to regulate the research and marketing of NDDS-related medicinal items and medical devices because of concerns about the efficacy and safety of medications in NDDS. Any medicine used in the biological system bears some danger of an unfavorable outcome. The risk-to-benefit ratio for most medications is positive, meaning the benefits of using the drug outweigh its risks. However, there have been tragic situations where medications have seriously harmed people. Significant adverse responses that go unrecognized are caused by harmful pharmaceuticals and fake or counterfeit medicines. Effective drug regulation is necessary due to these problems to guarantee the general public's safety and efficacy of medications.
Microemulsions are clear, stable, isotropic mixtures of oil, water, and surfactant, which are often mixed with a cosurfactant. These systems are currently of interest to pharmaceutical scientists because of their considerable potential to act as drug delivery vehicles by incorporating a wide range of drug molecules. The use of microemulsions and closely related micro emulsion-based systems as drug delivery vehicles is reviewed, particularly on recent developments and future directions.
The global novel drug delivery system market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant revenue contributor in the global novel drug delivery system market share and is expected to grow at a CAGR of 5.86% during the forecast period. Due to reasons like growth in research activities relevant to new medicines, an increase in funding for the discovery of innovative drugs, and rising public awareness of novel drug delivery methods, the United States is leading the market. The main factors driving the US market for novel drug delivery systems are the rising propensity for drug self-administration, advancements in injectable drug delivery systems, high adoption rates of new healthcare technology, and the high prevalence of chronic diseases. The Canadian market is well-established and has both local and international competitors competing fiercely. The nation's improved healthcare system offers high-quality service.
Europe is expected to grow at a CAGR of 6.08%, generating USD 97.81billion during the forecast period. The French market is growing owing to factors such as the increasing geriatric population and rising chronic disorders, leading to high demand for novel drug delivery systems. According to the Fondation de France, one in three French citizens has significant cardiovascular disease risk factors. Cardiovascular disorders, hypertension, diabetes, and other conditions drive the demand for medication delivery systems. Although cancer, neurological disorders, and infectious diseases pose more significant hazards to the population, cardiovascular diseases are determined to be the leading cause of mortality in the nation, according to a study published in Circulation Research in 2018. Drug delivery systems treat such disorders to decrease the likelihood of adverse effects. New product launches will also give the local market expansion opportunities.
Asia-Pacific is anticipated to grow significantly during the forecast period. China is the major player in the novel drug delivery system market. The main drivers of the examined market in China are the rising frequency of chronic diseases, including cancer and cardiovascular disease, and the expanding research on cutting-edge technologies in the pharmaceutical industry. To speed up product registration and safeguard intellectual property rights (IPR), China introduced new drug administration rules, according to the market report of Pharmaceutics China 2020, published in the American Journal of Advanced Drug Delivery. The Chinese medication was shown to have substantial anti-inflammatory benefits. Still, their widespread use in the clinic was hindered by their poor water-soluble ability, instability, and quick metabolism, according to a research article published in Chinese medicine in 2019.
The main drivers of the LAMEA market have been the rising elderly population, cancer, and infectious illness rates, and these factors together. In addition, according to a study published in BMC Systematic Reviews in 2018, South Africa is one of the nations on the continent that is actively engaged in nanomedicine research and product development, as well as a leader in health care services and biomedical research. The study aimed to determine which diseases in South Africa are treated with nanomedicine.
The global novel drug delivery system market is segmented by route of administration and mode of NDSS.
Based on the route of administration, the global novel drug delivery system is bifurcated into oral drugs, injectable drugs, pulmonary drugs, transdermal drugs, and others.
The injectable drug delivery system segment is the highest contributor to the market and is estimated to grow at a CAGR of 7.21% during the forecast period. Injectable drug delivery systems give drugs intravenously, intramuscularly, or subcutaneously. Injectable methods are routinely used for medications with low oral bioavailability, targeted drug administration, and delivery of medicines at the site of action. Injectable medication administration treats disorders such as ribose-5-phosphate isomerase deficiency, Wilson's disease, hemophilia, hepatitis C, diabetes, cystic fibrosis, and hormonal imbalance. To enhance the market share, companies in the prefilled syringes sector obtain government permission for a range of drugs injected into syringes.
The oral pathway has received the most attention among the several drug delivery methods because of its distinct benefits, which include prolonged and controllable distribution, convenience of administration, feasibility for solid formulations, patient compliance, cost-effectiveness, and others. Routine oral medication administration is typical. They are the most reliable drug delivery methods with successful local and systemic outcomes, and patients and doctors favor them for medication administration. Due to its greater flexibility in the formulation of the dose form compared to other routes, it is also a successful method for the regulated administration of medications. The popularity of this dosage form is primarily due to its ease of use and wide therapeutic index window, both of which reduce the likelihood of toxicity and adverse effects. However, its use is constrained due to the poor stability of peptides and proteins in the gastrointestinal tract.
Based on the mode of NDSS, the global novel drug delivery system is bifurcated into targeted, controlled, and modulated.
The targeted drug delivery system segment owns the highest market share and is expected to grow at a CAGR of 6.26% during the forecast period. Controlled and sustained drug delivery systems are used in targeted drug delivery. Due to a higher medicine concentration at the target location in the body, this drug delivery ensures increased efficacy. The medication is released at the site of action, which then adheres to the sick tissue. The medicine's slow, extended motion on the unhealthy tissue for an appropriate amount of treatment time is predicted to produce future benefits, which is one of the main advantages of this drug delivery technique. Due to the advantages of targeted medication administration, rising demand for technological developments, and higher efficacy requirements brought on by the burden of chronic diseases, the market for these products is expanding at a rapid rate. Additionally, ongoing research is being done to increase the efficacy of solid tumor treatment by using targeted medication delivery and better formulations and techniques.
Controlled medication delivery involves keeping particular drug concentration levels at the site of action for the desired time. Patients benefit from this method of drug delivery because it eliminates the need for repeated dosages, improves patient compliance, and ensures that the medication is used to its fullest potential. Control release dosage forms and polymeric controlled drug delivery systems are examples of controlled drug delivery systems. Controlled medication delivery systems are used in a broader range of situations due to their effectiveness and advantages. These systems are used mainly in oncology applications, gastrointestinal tract disorders, and the delivery of drugs to the eyes.